Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAX-7
- Development stage
- Preclinical
- Lead developer
- Guangzhou Zaiji Medical Technology
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MAX-7 is an investigational radiopharmaceutical currently in the preclinical stage of development by Maxinovel for the treatment of various solid tumors. Designed as a targeted therapy, MAX-7 aims to deliver a radioactive payload directly to tumor cells by binding to a specific, though currently undisclosed, cell-surface antigen or receptor. This approach is intended to maximize the therapeutic index by concentrating ionizing radiation within the tumor mass while minimizing systemic exposure and off-target toxicity. MAX-7 is part of Maxinovel's broader pipeline of next-generation oncology treatments, which includes both small molecule inhibitors and other radiopharmaceutical conjugates.
- Other names
- Compound MAX 7
Beyond the preview
Go deeper on MAX-7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAX-7.